Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of ZK-Epothilone (ZK-Epo; ZK-219477) in Combination With Carboplatin in Patients With Platinum-sensitive Recurrent Ovarian Cancer

NCT00325351 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00325351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00325351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of ZK-Epothilone (ZK-Epo; ZK-219477) in Combination With Carboplatin in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
August 24, 2006
Completion date
March 25, 2009
Enrollment
45 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian neoplasms